Skip to main content
. 2024 Apr 4;7:411. doi: 10.1038/s42003-024-06003-0

Fig. 6. Enzalutamide reduces DSRCT growth independent of AR.

Fig. 6

A Colony formation assays of JN-DSRCT-1 and BER-DSRCT shAR #1 and 3 cell lines treated for 14-days with vehicle or 10 µM of enzalutamide in conjunction with dox (+) addition to deplete AR (n = 2–3 independent samples). B Relative viability of JN-DSRCT-1 and BER-DSRCT shAR #3 cell lines pretreated with or without dox to deplete AR and then treated for 72 h with concentrations of enzalutamide or flutamide (n = 3 independent samples). C Western blot examining EWSR1::WT1, MERTK, LCK, and ACTIN of DSRCT cells treated with 0, 0.1, 1, or 10 µM enzalutamide for 72 h. Proteins of similar sizes were detected on the same membrane via chemiluminescent detection. D RT-qPCR of DSRCT cells treated for 72 h with vehicle ctrl (CTRL), 1 nM DHT (DHT), 10 µM enzalutamide (ENZ), or 1 nM DHT and 10 µM enzalutamide (DHT + ENZ) (n = 2 independent samples). E Heatmap of NR3 nuclear receptor expression in DSRCT tumors (n = 22). AR intensity was measured from matched IHC. F UMAP projections showing expression of AR, NR3C1, and ESR1 in snRNA-seq from three DSRCT patient-derived xenografts.